XASX
IPD
Market cap8mUSD
Jul 10, Last price
0.01AUD
1D
-16.67%
1Q
-66.67%
Jan 2017
-99.51%
IPO
-99.41%
Name
ImpediMed Ltd
Chart & Performance
P/E
—
P/S
0.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
27.68%
Rev. gr., 5y
17.25%
Revenues
13m
+23.31%
Net income
-23m
L+17.42%
CFO
-15m
L-17.67%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ImpediMed Limited is a medical technology firm that specializes in software solutions. The company is involved in the creation, production, and global distribution of sophisticated bioimpedance spectroscopy (BIS) equipment and its accompanying software applications, serving markets in Australia, North America, and beyond. Its principal offerings include: SOZO: A non-intrusive BIS device engineered for the evaluation of lymphedema and for tracking fluid levels in individuals afflicted with heart failure. SFB7: A single-channel, tetrapolar BIS instrument utilized to assess the body composition of healthy individuals. ImpediVET: Another single-channel, tetrapolar BIS device, tailored specifically for veterinary applications to measure fluid status and tissue characteristics in animals. ImpediMed primarily markets its advanced medical devices to healthcare institutions such as hospitals and clinics. The company was founded in 1999 and its headquarters are located in Pinkenba, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||